Updated 2022.
A review of Parkinson's clinical trials has been published. They found five trials that qualified as eligible for inclusion. Three of those trials used IV glutathione, and two used intranasal glutathione. Link here:
spandidos-publications.com/...
They found that treatment resulted in essentially no difference for UPDRS sections 1 and II. For UPDRS part III, which is the motor section, there was an average of 2.2 points improvement over control, and it was statistically significant. (Table 4C). The trials using intranasal treatment tried two different daily total dosages, 300 milligrams and 600 milligrams. The 600 milligram dosage got better results and I used that when calculating the above average.
The more recent of the intranasal studies can be found here:
researchgate.net/publicatio...
The 600 milligram dosage was taken as 200 milligrams three times daily. This 12 week trial did find an improvement of 2.2 points in the UPDRS part III. This was statistically significant versus baseline but not versus placebo, which showed a only a .3 point improvement.
I regard a two point improvement as modest. Personally I tried nebulized glutathione, which is inhaled rather than intranasal, and it did not do anything for me.